– FOR DISCUSSION PURPOSES WITH PROFESSIONAL INVESTORS ONLY –
The British Innovation Fund continues to perform well in 2020, with its portfolio companies well placed to continue to progress. Of particular note is portfolio company Attomarker, in which the Fund has a 25% stake. This point of care diagnostics business is at the forefront of the fight against COVID-19, currently conducting tests at St Thomas’s NHS Hospital in London to potentially use its unique technology to deliver a rapid multiplex test for the disease, with promising early results shown.
Please read our full British Innovation Fund Investor Communication below.
Please contact us if you would like to learn more about the British Innovation Fund and our commitment to the Best of British Science & Innovation.